Isomorphic Labs Secures $2.1 Billion to Revolutionize AI-Driven Drug Discovery, ETEnterpriseai
Isomorphic Labs Secures $2.1 Billion to Revolutionize AI-Driven Drug Discovery, ETEnterpriseai
Publish Date: 2026-05-13 02:30:00
Source Domain: enterpriseai.economictimes.indiatimes.com
- Isomorphic Labs raises $2.1 billion in new funding led by Thrive Capital to expand its AI-driven drug discovery platform.
- Existing investors, including Google Ventures, and new backers such as MGX, Temasek, and CapitalG participated in the round.
- This funding marks a significant increase from the $600 million raised last year, also led by Thrive Capital.
- The London-based company, founded in 2021 as a spin-off of Google DeepMind, focuses on leveraging AI breakthroughs like AlphaFold to predict protein structures for effective drug design.
- Founder and CEO Demis Hassabis stated the company aims to solve diseases and expects to initiate its first clinical trials by the end of 2026.
- Isomorphic Labs did not disclose its latest valuation but is scaling its technology after demonstrating the effectiveness of its AI-based approach.
